Medizin
Refine
Year of publication
- 2018 (472) (remove)
Document Type
- Article (439)
- Contribution to a Periodical (9)
- Doctoral Thesis (9)
- Part of Periodical (9)
- Book (3)
- Conference Proceeding (1)
- Preprint (1)
- Report (1)
Has Fulltext
- yes (472) (remove)
Is part of the Bibliography
- no (472)
Keywords
- breast cancer (15)
- Mammakarzinom (10)
- Behandlung (8)
- inflammation (7)
- CDK4/6 (6)
- Metastasen (6)
- Neuroscience (6)
- PD1/PDL1 (6)
- Studien (6)
- treatment (6)
Institute
- Medizin (472)
- Präsidium (14)
- Sonderforschungsbereiche / Forschungskollegs (14)
- Exzellenzcluster Makromolekulare Komplexe (9)
- Biowissenschaften (8)
- Sportwissenschaften (8)
- Exzellenzcluster Herz-Lungen-System (7)
- Georg-Speyer-Haus (6)
- Pharmazie (6)
- Psychologie (6)
Background: Conversion from calcineurin inhibitor (CNI) therapy to a mammalian target of rapamycin (mTOR) inhibitor following kidney transplantation may help to preserve graft function. Data are sparse, however, concerning the impact of conversion on posttransplant diabetes mellitus (PTDM) or the progression of pre-existing diabetes.
Methods: PTDM and other diabetes-related parameters were assessed post hoc in two large open-label multicenter trials. Kidney transplant recipients were randomized (i) at month 4.5 to switch to everolimus or remain on a standard cyclosporine (CsA)-based regimen (ZEUS, n = 300), or (ii) at month 3 to switch to everolimus, remain on standard CNI therapy or convert to everolimus with reduced-exposure CsA (HERAKLES, n = 497).
Results: There were no significant differences in the incidence of PTDM between treatment groups (log rank p = 0.97 [ZEUS], p = 0.90 [HERAKLES]). The mean change in random blood glucose from randomization to month 12 was also similar between treatment groups in both trials for patients with or without PTDM, and with or without pre-existing diabetes. The change in eGFR from randomization to month 12 showed a benefit for everolimus versus comparator groups in all subpopulations, but only reached significance in larger subgroups (no PTDM or no pre-existing diabetes).
Conclusions: Within the restrictions of this post hoc analysis, including non-standardized diagnostic criteria and limited glycemia laboratory parameters, these data do not indicate any difference in the incidence or severity of PTDM with early conversion from a CsA-based regimen to everolimus, or in the progression of pre-existing diabetes.
Trial registration: clinicaltrials.gov, NCT00154310 (registered September 2005) and NCT00514514 (registered August 2007); EudraCT (2006-007021-32 and 2004-004346-40).
The aim of this systematic review and meta-analysis was to compare the peri-implant vertical bone loss of immediate loading of implant crowns using the one abutment at one time (AOT) protocol and implants with abutment removal (AR). This systematic review with meta-analysis was reported according to the PRISMA statement, with guidance from the Cochrane Collaboration Handbook. A total of 103 publications were identified in the PubMed database and reference lists of examined articles. After the screening of titles and abstracts, the eligibility of eight full-text articles was assessed. Five studies published between 2010 and 2015 were included in the meta-analysis. There was less peri-implant vertical bone loss at implants using an AOT protocol than at implants using AR protocol (WMD -0.19, 95% CI -0.26 to -0.13; p<0.0001; random-effects model). In conclusion, the use of the AOT protocol with platform-switched Morse implants results in less bone loss than do AR procedures, but this effect may not be clinically relevant. The preservation of marginal bone level achieved with the AOT protocol may not enhance the aesthetics. These results should be interpreted with caution.
Aim: Reactive oxygen species (ROS) produced by enzymes of the NADPH oxidase family serve as second messengers for cellular signaling. Processes such as differentiation and proliferation are regulated by NADPH oxidases. In the intestine, due to the exceedingly fast and constant renewal of the epithelium both processes have to be highly controlled and balanced. Nox1 is the major NADPH oxidase expressed in the gut, and its function is regulated by cytosolic subunits such as NoxO1. We hypothesize that the NoxO1-controlled activity of Nox1 contributes to a proper epithelial homeostasis and renewal in the gut.
Results: NoxO1 is highly expressed in the colon. Knockout of NoxO1 reduces the production of superoxide in colon crypts and is not subsidized by an elevated expression of its homolog p47phox. Knockout of NoxO1 increases the proliferative capacity and prevents apoptosis of colon epithelial cells. In mouse models of dextran sulfate sodium (DSS)-induced colitis and azoxymethane/DSS induced colon cancer, NoxO1 has a protective role and may influence the population of natural killer cells.
Conclusion: NoxO1 affects colon epithelium homeostasis and prevents inflammation.
Background and aims: Spontaneous bacterial peritonitis (SBP) is a severe complication of decompensated cirrhosis. The prevalence of multidrug-resistant organisms (MDROs) in patients with cirrhosis is increasing. Identification of patients at risk for SBP due to MDROs (ie, SBP with the evidence of MDROs or Stenotrophomonas maltophilia in ascitic culture, MDRO-SBP) is crucial to the early adaptation of antibiotic treatment in such patients. We therefore investigated whether MDROs found in ascitic cultures can also be found in specimens determined by noninvasive screening procedures.
Patients and methods: This retrospective study was conducted at the liver center of the University Hospital Frankfurt, Germany. Between 2011 and 2016, patients with cirrhosis were included upon diagnosis of SBP and sample collection of aerobic/anaerobic ascitic cultures. Furthermore, the performance of at least one complete MDRO screening was mandatory for study inclusion.
Results: Of 133 patients diagnosed with SBP, 75 (56.4%) had culture-positive SBP and 22 (16.5%) had MDRO-SBP. Multidrug-resistant Escherichia coli (10/22; 45.5%) and vancomycin-resistant enterococci (7/22; 36.4%) resembled the major causatives of MDRO-SBP. Rectal swabs identified MDROs in 17 of 22 patients (77.3%) who developed MDRO-SBP with a time-dependent sensitivity of 77% and 87% after 30 and 90 days upon testing, while negative predictive value was 83% and 76%, respectively. The majority of patients were included from intensive care unit or intermediate care unit.
Conclusion: MDRO screening may serve as a noninvasive diagnostic tool to identify patients at risk for MDRO-SBP. Patients with decompensated cirrhosis should be screened for MDROs from the first day of inpatient treatment onward.
Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age. OAT became less complicate with the introduction of non-vitamin K oral anticoagulants (NOAC) OAT because of easier handling, favorable risk-benefit profile, reduced rates of ICH compared to vitamin K antagonists and no need for routine coagulation testing. Consequently, despite a better safety profile of NOAC the number of patients with OAC-ICH will increase. The mortality and complication rates of OAC-ICH are high and therefore they are the most feared complication of OAT. Immediate normalization of coagulation is the main goal and therefore knowledge of pharmacodynamics and coagulation status is essential. Laboratory measurements of anticoagulant activity in NOAC patients is challenging as specific tests are not widely available. More accessible tests such as the prothrombin time and activated partial thromboplastin time have important limitations. In dabigatran-associated ICH 5 g Idarucizumab should be administered. In rivaroxaban and apixaban-associated ICHs administration of andexanet alpha should be considered. Prothrombin complex concentrate may be considered if andexanet alpha is not available or in case of an ICH associated with edoxaban.
The adaptor molecule stimulator of IFN genes (STING) is central to production of type I IFNs in response to infection with DNA viruses and to presence of host DNA in the cytosol. Excessive release of type I IFNs through STING-dependent mechanisms has emerged as a central driver of several interferonopathies, including systemic lupus erythematosus (SLE), Aicardi–Goutières syndrome (AGS), and stimulator of IFN genes-associated vasculopathy with onset in infancy (SAVI). The involvement of STING in these diseases points to an unmet need for the development of agents that inhibit STING signaling. Here, we report that endogenously formed nitro-fatty acids can covalently modify STING by nitro-alkylation. These nitro-alkylations inhibit STING palmitoylation, STING signaling, and subsequently, the release of type I IFN in both human and murine cells. Furthermore, treatment with nitro-fatty acids was sufficient to inhibit production of type I IFN in fibroblasts derived from SAVI patients with a gain-of-function mutation in STING. In conclusion, we have identified nitro-fatty acids as endogenously formed inhibitors of STING signaling and propose for these lipids to be considered in the treatment of STING-dependent inflammatory diseases.
Upregulations of neuronal nitric oxide synthase (nNOS) in the rodent brain have been associated with neuronal aging. To address underlying mechanisms we generated SH-SY5Y neuronal cells constitutively expressing nNOS at a level similar to mouse brain (nNOS+ versus MOCK). Initial experiments revealed S-nitrosylations (SNO) of key players of protein homeostasis: heat shock cognate HSC70/HSPA8 within its nucleotide-binding site, and UBE2D ubiquitin conjugating enzymes at the catalytic site cysteine. HSPA8 is involved in protein folding, organelle import/export and chaperone-mediated LAMP2a-dependent autophagy (CMA). A set of deep redox and full proteome analyses, plus analysis of autophagy, CMA and ubiquitination with rapamycin and starvation as stimuli confirmed the initial observations and revealed a substantial increase of SNO modifications in nNOS+ cells, in particular targeting protein networks involved in protein catabolism, ubiquitination, carbohydrate metabolism and cell cycle control. Importantly, NO-independent reversible oxidations similarly occurred in both cell lines. Functionally, nNOS caused an accumulation of proteins, including CMA substrates and loss of LAMP2a. UBE2D activity and proteasome activity were impaired, resulting in dysregulations of cell cycle checkpoint proteins. The observed changes of protein degradation pathways caused an expansion of the cytoplasm, large lysosomes, slowing of the cell cycle and suppression of proliferation suggesting a switch of the phenotype towards aging, supported by downregulations of neuronal progenitor markers but increase of senescence-associated proteins. Hence, upregulation of nNOS in neuronal cells imposes aging by SNOing of key players of ubiquitination, chaperones and of substrate proteins leading to interference with crucial steps of protein homeostasis.
Einleitung: Die chronische Hepatitis C gehört zu den häufigen Ursachen einer Leberzirrhose. Durch die Entwicklung von direkt antiviralen Medikamenten (direct acting antiviral agent, DAA) können Heilungsraten von über 90% bei chronischer Hepatitis C erreicht werden. Der Einfluss des Therapieerfolgs auf Fibroseregression und portale Hypertension ist insbesondere für Patienten mit Leberzirrhose bisher nicht ausreichend geklärt. Elastographische Messungen von Leber und Milz können als Surrogatmarker zur nicht-invasiven Evaluation von Fibroseregression und Rückgang von portaler Hypertension dienen. Ziel der vorliegenden Arbeit war die Evaluation der Dynamik von Leberfibrose und portaler Hypertension mittels transienter Elastographie der Leber (L-TE) und Acoustic Radiation Force Impulse Elastographie von Leber (L-ARFI) und Milz (M-ARFI) bei Patienten mit DAA-induziertem anhaltendem virologischen Ansprechen (sustained virological response, SVR) und Hepatitis C Virus (HCV) assoziierter Leberzirrhose.
Patienten und Methoden: In dieser prospektiven, monozentrischen Studie wurden Daten von 56 Patienten mit chronischer Hepatitis C und assoziierter Leberzirrhose analysiert, die eine SVR nach 12-24 Wochen antiviraler Hepatitis C Therapie mit DAA's erreichten. Dabei wurden zu vier Zeitpunkten (Therapiebeginn [BL], Therapieende [EOT], 24 Wochen nach Therapieende [FU24] und 48 Wochen nach Therapieende [FU48]) Messungen vorgenommen. Zusätzlich wurden Leberzirrhose assoziierte Scores und Komplikationen sowie Laborparameter erhoben.
Ergebnisse: Die elastographischen Messungen der Leber zeigten signifikante Verbesserungen im Studienverlauf, am stärksten während der antiviralen Therapie. Im L-TE zeigten sich Verbesserungen zwischen BL [Median(Min-Max), 32,45(9,1-75)kPa] und FU48[Median (Min-Max), 17,1 (3,7-59,3) kPa] (p<0,0001) und im L-ARFI zwischen BL [Median (Min-Max), 2,7 (1,2-4,1) m/s] und FU24 [Median (Min-Max), 2,5 (1,2-3,9)m/s (p=0,011), wobei signifikante Verbesserungen (≥30%) bei 35/49 (71%) Patienten im L-TE und bei 6/55 (11%) im L-ARFI auftraten. Die M-ARFI Messungen als Korrelat der portalen Hypertension, zeigten kaum Veränderungen. Die medianen Werte blieben zwischen BL [Median (Min-Max), 3,4 (1,9-4,3) m/s] und FU48 [Median (Min-Max), 3,4(2-4,4) m/s] konstant (p=0,9). Nur 2/54 (4%) der Patentien zeigten signifikante Verbesserungen. In der univariaten Analyse zeigten sich 65 als positive Einflussfaktoren der L-TE- und L-ARFI-Verbesserung ein MELD Score bis 10 sowie ein BMI bis 30 kg/m².
Diskussion und Schlussfolgerung: In Zusammenschau der Ergebnisse kann bei einem Teil der Patienten von einer Fibroseregression und dem Rückgang der portalen Hypertension nach DAA-basierter, interferon-freier antiviraler Therapie ausgegangen werden. Die mittels L-ARFI und L-TE gemessene Verbesserung der Lebersteifigkeit unter antiviraler Therapie scheint auf einer Verbesserung von Nekroinflammation und Leberfibrose zu basieren. Bei Nichtbeachtung des Einflusses der Nekroinflammation auf nicht-invasive Messungen der Lebersteifigkeit kann es zur Überschätzung der Fibroseregression nach SVR kommen. Da es sich bei der Zirrhose- bzw. Fibroseregression anscheinend um einen langsamen Prozess handelt, sind ausreichend lange Nachbeobachtungszeiten in entsprechenden Studien zu fordern. Für die mit einer Leberzirrhose assoziierte portale Hypertension gelten ähnliche Überlegungen.
Our ability to select relevant information from the environment is limited by the resolution of attention – i.e., the minimum size of the region that can be selected. Neural mechanisms that underlie this limit and its development are not yet understood. Functional magnetic resonance imaging (fMRI) was performed during an object tracking task in 7- and 11-year-old children, and in young adults. Object tracking activated canonical fronto-parietal attention systems and motion-sensitive area MT in children as young as 7 years. Object tracking performance improved with age, together with stronger recruitment of parietal attention areas and a shift from low-level to higher-level visual areas. Increasing the required resolution of spatial attention – which was implemented by varying the distance between target and distractors in the object tracking task – led to activation increases in fronto-insular cortex, medial frontal cortex including anterior cingulate cortex (ACC) and supplementary motor area, superior colliculi, and thalamus. This core circuitry for attentional precision was recruited by all age groups, but ACC showed an age-related activation reduction. Our results suggest that age-related improvements in selective visual attention and in the resolution of attention are characterized by an increased use of more functionally specialized brain regions during the course of development.
Neuro-ophthalmological signs and symptoms are common in the emergency department but are a frequent source of diagnostic uncertainties. However, neuro-ophthalmological signs often allow a precise neuro-topographical localization of the clinical problem. A practical concept is presented how to perform a neuro-ophthalmological examination at the bedside and to interpret key findings under the aspect of emergency medicine with limited resources.